Class Action Targets Regenxbio Over Alleged Misleading RGX‑111 Early Data Claims

Regulatory and Clinical Scrutiny Focuses on RGX‑111 Data Claims

Regulators and the broader gene therapy community face heightened scrutiny as a new class action alleges that Regenxbio is misrepresenting early clinical data for its one‑time gene therapy RGX‑111. The complaint, announced by Rosen Law Firm, asserts that the company touts positive biomarker and safety signals from an ongoing Phase I/II study for severe Mucopolysaccharidosis Type I (Hurler syndrome) before the full truth emerges, raising questions about the timing and completeness of public disclosures from clinical developers.

The litigation underscores a wider concern in the nascent gene therapy sector: how sponsors communicate interim trial results and safety signals from early‑stage studies. Observers note that premature or selective disclosure of biomarker improvements or tolerability could distort the understanding of a therapy’s risk‑benefit profile among regulators, patient groups and clinical partners. That risk is amplified in rare disease programs, where single‑arm and small cohort designs make interpretive caution essential.

Beyond legal arguments, the case spotlights operational and ethical pressures on developers of novel biologics. Companies advancing one‑time genetic treatments balance rapid enrollment and compassionate use considerations against the need for rigorous, reproducible evidence before claiming clinical benefit. Regulators and institutional review boards increasingly focus on data transparency and the context in which interim results are communicated, which may affect trial protocols, monitoring and sponsor press practices across the industry.

Class Action Filed, Lead Plaintiff Deadline Looms

Rosen Law Firm initiates the class action on behalf of purchasers of Regenxbio securities between Feb. 9, 2022 and Jan. 27, 2026 and notes a lead plaintiff must move by April 14, 2026. The firm says the complaint alleges materially false and misleading statements or omissions regarding RGX‑111’s efficacy and safety from the Phase I/II program.

The firm offers representation on a contingency fee basis and provides a submission portal and contact details for potentially eligible investors. Rosen also cites its track record in securities litigation while urging prompt action to preserve rights.